Characterization of diverse subvariants of the meningococcal factor H (fH) binding protein for their ability to bind fH, to mediate serum resistance, and to induce bactericidal antibodies

Infection and Immunity

Volumn 79, Issue 2, 2011, Pages 970-981

  Seib, Kate L ^a   Brunelli, Brunella ^a   Brogioni, Barbara ^a   Palumbo, Emmanuelle ^a   Bambini, Stefania ^a   Muzzi, Alessandro ^a   DiMarcello, Federica ^a   Marchi, Sara ^a   Van Der Ende, Arie ^b   Aricó, Beatrice ^a   Savino, Silvana ^a   Scarselli, Maria ^a   Comanducci, Maurizio ^a   Rappuoli, Rino ^a   Giuliani, Marzia M ^a   Pizza, Mariagrazia ^a  

^a NOVARTIS VACCINES AND DIAGNOSTICS   (Italy)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIUM ANTIBODY; BINDING PROTEIN; COMPLEMENT FACTOR H; CROSS REACTING ANTIBODY; FACTOR H BINDING PROTEIN; UNCLASSIFIED DRUG;

ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ARTICLE; BINDING AFFINITY; CLINICAL ASSESSMENT; FLOW CYTOMETRY; GENETIC ENGINEERING; HOST RESISTANCE; IMMUNE RESPONSE; NEISSERIA MENINGITIDIS; NONHUMAN; PHYLOGENY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN STABILITY; SURFACE PLASMON RESONANCE; WESTERN BLOTTING;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, BACTERIAL; BACTERIAL PROTEINS; COMPLEMENT FACTOR H; COMPLEMENT SYSTEM PROTEINS; FEMALE; GENETIC VARIATION; HUMANS; MENINGOCOCCAL INFECTIONS; MICE; MOLECULAR SEQUENCE DATA; NEISSERIA MENINGITIDIS; PHYLOGENY; PROTEIN BINDING; RABBITS;

EID: 79251470393     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.00891-10     Document Type: Article

References (57)

1. Bambini, S., et al. 2009. Distribution and genetic variability of three vaccine components in a panel of strains representative of the diversity of serogroup B meningococcus. Vaccine 27:2794-2803.
2. Beernink, P. T., and D. M. Granoff. 2009. The modular architecture of meningococcal factor H-binding protein. Microbiology 155:2873-2883.
3. Borrow, R., et al. 2005. Interlaboratory standardization of the measurement of serum bactericidal activity by using human complement against meningococcal serogroup b, strain 44/76-SL, before and after vaccination with the Norwegian MenBvac outer membrane vesicle vaccine. Clin. Diagn. Lab. Immunol. 12:970-976.
4. Brehony, C., D. J. Wilson, and M. C. Maiden. 2009. Variation of the factor H-binding protein of Neisseria meningitidis. Microbiology 155:4155-4169.
5. Brunelli, B., et al. Influence of sequence variability on bactericidal activity sera induced by factor H binding protein variant 1.1 Vaccine, in press.
6. Cantini, F., et al. 2009. Solution structure of the factor H binding protein, a survival factor and protective antigen of Neisseria meningitidis. J. Biol. Chem. 284:9022-9026.
7. Du, L., Y. Zhou, and S. Jiang. 2010. Research and development of universal influenza vaccines. Microbes and infection / Institut Pasteur. 12:280-286.
8. Dunphy, K. Y., P. T. Beernink, B. Brogioni, and D. M. Granoff. 1 November 2010. Effect of factor H-binding protein sequence variation on factor H binding and survival of Neisseria meningitidis in human blood. Infect. Immun. doi:10.1128/IAI.00849-10.
9. Edgar, R. C. 2004. MUSCLE: multiple sequence alignment with high accuracy and high throughput. Nucleic Acids Res. 32:1792-1797.
10. Finne, J., D. Bitter-Suermann, C. Goridis, and U. Finne. 1987. An IgG monoclonal antibody to group B meningococci cross-reacts with developmentally regulated polysialic acid units of glycoproteins in neural and extraneural tissues. J. Immunol. 138:4402-4407.
11. Fletcher, L. D., et al. 2004. Vaccine potential of the Neisseria meningitidis 2086 lipoprotein. Infect. Immun. 72:2088-2100.
12. Giuliani, M. M., et al. 2006. A universal vaccine for serogroup B meningococcus. Proc. Natl. Acad. Sci. U. S. A. 103:10834-10839.
13. Giuliani, M. M., et al. 2010. Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. Vaccine 28:5023-5030.
14. Giuliani, M. M., et al. 2005. The region comprising amino acids 100 to 255 of Neisseria meningitidis lipoprotein GNA 1870 elicits bactericidal antibodies. Infect. Immun. 73:1151-1160.
15. Granoff, D. M., J. A. Welsch, and S. Ram. 2009. Binding of complement factor H (fH) to Neisseria meningitidis is specific for human fH and inhibits complement activation by rat and rabbit sera. Infect. Immun. 77:764-769.
16. Haralambous, E., et al. 2006. Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients. Scand. J. Infect. Dis. 38:764-771.
17. Ingram, G., et al. 2010. Complement regulator factor H as a serum biomarker of multiple sclerosis disease state. Brain 133:1602-1611.
18. Jacobsson, S., et al. 2009. Prevalence and sequence variations of the genes encoding the five antigens included in the novel 5CVMB vaccine covering group B meningococcal disease. Vaccine 27:1579-1584.
19. Jacobsson, S., P. Molling, and P. Olcen. 2009. Seroprevalence of antibodies against fHbp and NadA, two potential vaccine antigens for Neisseria meningitidis. Vaccine 27:5755-5759.
20. Jennings, M. P., D. W. Hood, I. R. Peak, M. Virji, and E. R. Moxon. 1995. Molecular analysis of a locus for the biosynthesis and phase-variable expression of the lacto-N-neotetraose terminal lipopolysaccharide structure in Neisseria meningitidis. Mol. Microbiol. 18:729-740.
21. Jiang, H. Q., et al. 2010. Broad vaccine coverage predicted for a bivalent recombinant factor H binding protein based vaccine to prevent serogroup B meningococcal disease. Vaccine 28:6086-6093.
22. Jones, D. T., W. R. Taylor, and J. M. Thornton. 1992. The rapid generation of mutation data matrices from protein sequences. Comput. Appl. Biosci. 8:275-282.
23. Lewis, L. A., et al. 2010. The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e1001027.
24. Lewis, S., M. Sadarangani, J. C. Hoe, and A. J. Pollard. 2009. Challenges and progress in the development of a serogroup B meningococcal vaccine. Expert Rev. Vaccines 8:729-745.
25. Lucidarme, J., et al. 2010. Characterisation of fHbp, nhba (gna2132), nadA, porA and sequence type in group B meningococcal case isolates collected in England and Wales during January 2008, and potential coverage of an investigational group B meningococcal vaccine. Clin. Vaccine Immunol. 17:919-929.
26. Madico, G., et al. 2006. The meningococcal vaccine candidate GNA1870 binds the complement regulatory protein factor H and enhances serum resistance. J. Immunol. 177:501-510.
27. Masignani, V., et al. 2003. Vaccination against Neisseria meningitidis using three variants of the lipoprotein GNA1870. J. Exp. Med. 197:789-799.
28. Mathew, S., and G. D. Overturf. 2006. Complement and properidin deficiencies in meningococcal disease. Pediatr. Infect. Dis. J. 25:255-256.
29. McNeil, L. K., et al. 2009. Detection of LP2086 on the cell surface of Neisseria meningitidis and its accessibility in the presence of serogroup B capsular polysaccharide. Vaccine 27:3417-3421.
30. Meri, S., M. Jordens, and H. Jarva. 2008. Microbial complement inhibitors as vaccines. Vaccine 26(Suppl. 8):I113-I117.
31. Meyer, T. F. 1991. Evasion mechanisms of pathogenic neisseriae. Behring Inst. Mitt. 88:194-199.
32. Murphy, E., et al. 2009. Sequence diversity of the factor H binding protein vaccine candidate in epidemiologically relevant strains of serogroup B Neisseria meningitidis. J. Infect. Dis. 200:379-389.
33. Nedelec, J., J. Boucraut, J. M. Garnier, D. Bernard, and G. Rougon. 1990. Evidence for autoimmune antibodies directed against embryonic neural cell adhesion molecules (N-CAM) in patients with group B meningitis. J. Neuroimmunol. 29:49-56.
34. Nicholls, J. M., R. W. Chan, R. J. Russell, G. M. Air, and J. S. Peiris. 2008. Evolving complexities of influenza virus and its receptors. Trends Microbiol. 16:149-157.
35. Nielsen, H. E., et al. 1989. Hereditary, complete deficiency of complement factor H associated with recurrent meningococcal disease. Scand. J. Immunol. 30:711-718.
36. Noah, N., and B. Henderson. 2002. Surveillance of bacterial meningitis in Europe 1997/1998. Communicable Disease Surveillance Centre, London, England.
37. Persson, C. G., et al. 1998. Plasma-derived proteins in airway defence, disease and repair of epithelial injury. Eur. Respir. J. 11:958-970.
38. Persson, J., B. Beall, S. Linse, and G. Lindahl. 2006. Extreme sequence divergence but conserved ligand-binding specificity in Streptococcus pyogenes M protein. PLoS Pathog. 2:e47.
39. Pizza, M., J. Donnelly, and R. Rappuoli. 2008. Factor H-binding protein, a unique meningococcal vaccine antigen. Vaccine 26S:146-148.
40. Plested, J. S., J. A. Welsch, and D. M. Granoff. 2009. Ex vivo model of meningococcal bacteremia using human blood for measuring vaccine-induced serum passive protective activity. Clin. Vaccine Immunol. 16:785-791.
41. Ram, S., and U. Vogel. 2006. Role of complement in defence against meningococcal infection, p. 273-293. In M. Frosch and M. C. J. Maiden (ed.), Handbook of meningococcal disease infection: biology, vaccination, clinical management. Wiley-VCH Verlag GmbH, Weinheim, Germany.
42. Rappuoli, R. 2008. The application of reverse vaccinology, Novartis MenB vaccine developed by design, p. 81. Progr. and Abstr. 16th Int. Pathog. Neisseria Conf., Rotterdam, Netherlands. Australian Society for Microbiology, Melbourne, Australia.
43. Rodriguez de Cordoba, S., J. Esparza-Gordillo, E. Goicoechea de Jorge, M. Lopez-Trascasa, and P. Sanchez-Corral. 2004. The human complement factor H: functional roles, genetic variations and disease associations. Mol. Immunol. 41:355-367.
44. Rosenstein, N. E., et al. 1999. The changing epidemiology of meningococcal disease in the United States, 1992-1996. J. Infect. Dis. 180:1894-1901.
45. Rosenstein, N. E., B. A. Perkins, D. S. Stephens, T. Popovic, and J. M. Hughes. 2001. Meningococcal disease. N. Engl. J. Med. 344:1378-1388.
46. Saitou, N., and M. Nei. 1987. The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol. Biol. Evol. 4:406-425.
47. Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. Molecular cloning: a laboratory manual, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY.
48. Sarkari, J., N. Pandit, E. R. Moxon, and M. Achtman. 1994. Variable expression of the Opc outer membrane protein in Neisseria meningitidis is caused by size variation of a promoter containing poly-cytidine. Mol. Microbiol. 13:207-217.
49. Schneider, M. C., et al. 2009. Neisseria meningitidis recruits factor H using protein mimicry of host carbohydrates. Nature 458:890-893.
50. Seib, K. L., et al. 2009. Factor H-binding protein is important for meningococcal survival in human whole blood and serum and in the presence of the antimicrobial peptide LL-37. Infect. Immun. 77:292-299.
51. Shaughnessy, J., L. A. Lewis, H. Jarva, and S. Ram. 2009. Functional comparison of the binding of factor H short consensus repeat 6 (SCR 6) to factor H binding protein from Neisseria meningitidis and the binding of factor H SCR 18 to 20 to Neisseria gonorrhoeae porin. Infect. Immun. 77:2094-2103.
52. Sorensen, O., J. B. Cowland, J. Askaa, and N. Borregaard. 1997. An ELISA for hCAP-18, the cathelicidin present in human neutrophils and plasma. J. Immunol. Methods 206:53-59.
53. Stephens, D. S. 2007. Conquering the meningococcus. FEMS Microbiol. Rev. 31:3-14.
54. Tamura, K., J. Dudley, M. Nei, and S. Kumar. 2007. MEGA4: Molecular Evolutionary Genetics Analysis (MEGA) software version 4.0. Mol. Biol. Evol. 24:1596-1599.
55. Vandermeer, J., Q. Sha, A. P. Lane, and R. P. Schleimer. 2004. Innate immunity of the sinonasal cavity: expression of messenger RNA for complement cascade components and toll-like receptors. Arch. Otolaryngol. Head Neck Surg. 130:1374-1380.
56. Welsch, J. A., S. Ram, O. Koeberling, and D. M. Granoff. 2008. Complement-dependent synergistic bactericidal activity of antibodies against factor H-binding protein, a sparsely distributed meningococcal vaccine antigen. J. Infect. Dis. 197:1053-1061.
57. Zhou, T., et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.